Press releases and articles

EUROIMMUN and Homed-IQ offer Corporate COVID-19 Antibody Testing Program

With the Corporate COVID-19 Antibody Testing Program, EUROIMMUN gives companies the possibility to offer to their staff what EUROIMMUN has already offered to their own employees: an easy, ...

Exotic emerging diseases

Emerging infectious diseases is a term for new infectious diseases in humans that have either newly appeared in a population or have already existed but are rapidly increasing in incidence or ...

Christmas donations for charitable projects

Traditionally, Christmas is the time to reflect on what you have achieved and to turn your attention to those who are less well off.

The PerkinElmer Global Innovation Awards 2021 ceremony

For several weeks PerkinElmer, Inc. has been collecting nominations for a variety of Global Innovation Awards across all companies of the Group. EUROIMMUN has also suggested five colleagues from its ...

New guideline recognises anti-PLA2R as a significant biomarker for membranous nephropathy

In October 2021, the organisation KDIGO (Kidney Disease: Improving Clinical Outcomes) published an updated version of the clinical guideline for the management of patients with glomerulonephritis. ...

T cells: Important building blocks of immune protection against SARS-CoV-2

It is becoming increasingly clear that not only antibodies against SARS-CoV-2 play a role in building immunity against the coronavirus. T cells, as part of the cellular immune response, also have ...

The flu season is getting started

After a virtually non-existent flu season in 2020/2021 and with the revival of public life and the relaxation of social distancing measures, there is increasing concern that a large flu wave could ...

New partnership: IDS and EUROIMMUN

We are delighted to welcome Immunodiagnostic Systems Holding (IDS) as the newest member of the PerkinElmer family. The acquisition of the British diagnostics company was officially closed in July ...

Impact of SARS-CoV-2 variants on antibody tests

EUROIMMUN Launches SARS-CoV-2 NeutraLISA Assay to Determine the Neutralizing Capacity of Anti-SARS-CoV-2 Antibodies

EUROIMMUN, a PerkinElmer, Inc. Company, today announced the launch of the SARS-CoV-2 NeutraLISA assay, a surrogate neutralization test intended for the detection of neutralizing antibodies against ...

Back to top